-
1
-
-
0034124811
-
Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the cooperative cardiovascular project
-
Chertow GM, Normand SL, Silva LR, McNeil BJ: Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 35:1044-1051, 2000
-
(2000)
Am J Kidney Dis
, vol.35
, pp. 1044-1051
-
-
Chertow, G.M.1
Normand, S.L.2
Silva, L.R.3
McNeil, B.J.4
-
2
-
-
0036711313
-
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention
-
Fox KA, Antman EM, Cohen M, Bigonzi F, ESSENCE/TIMI 11B Investigators: Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 90:477-482, 2002
-
(2002)
Am J Cardiol
, vol.90
, pp. 477-482
-
-
Fox, K.A.1
Antman, E.M.2
Cohen, M.3
Bigonzi, F.4
-
3
-
-
0037438875
-
Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention
-
Wong GC, Giugliano RP, Antman EM: Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289:331-342, 2003
-
(2003)
JAMA
, vol.289
, pp. 331-342
-
-
Wong, G.C.1
Giugliano, R.P.2
Antman, E.M.3
-
4
-
-
2242477091
-
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
-
The EPIC Investigation
-
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330:956-961, 1994
-
(1994)
N Engl J Med
, vol.330
, pp. 956-961
-
-
-
5
-
-
1842369101
-
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
-
The EPILOG Investigators
-
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336:1689-1696, 1997
-
(1997)
N Engl J Med
, vol.336
, pp. 1689-1696
-
-
-
6
-
-
0035897893
-
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
-
Simoons ML, GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357:1915-1924, 2001
-
(2001)
Lancet
, vol.357
, pp. 1915-1924
-
-
Simoons, M.L.1
-
7
-
-
0030858230
-
Low-molecular-weight heparins
-
Weitz JI: Low-molecular-weight heparins. N Engl J Med 337:688-698, 1997
-
(1997)
N Engl J Med
, vol.337
, pp. 688-698
-
-
Weitz, J.I.1
-
8
-
-
0022559153
-
Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure
-
Follea G, Laville M, Pozet N, Dechavanne M: Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 16:147-151, 1986
-
(1986)
Haemostasis
, vol.16
, pp. 147-151
-
-
Follea, G.1
Laville, M.2
Pozet, N.3
Dechavanne, M.4
-
9
-
-
0035146530
-
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
-
Brophy DF, Wazny LD, Gehr TW, Comstock TJ, Venitz J: The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 21:168-174, 2001
-
(2001)
Pharmacotherapy
, vol.21
, pp. 168-174
-
-
Brophy, D.F.1
Wazny, L.D.2
Gehr, T.W.3
Comstock, T.J.4
Venitz, J.5
-
10
-
-
0036723925
-
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis
-
Hainer JS, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA: Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 40:531-538, 2002
-
(2002)
Am J Kidney Dis
, vol.40
, pp. 531-538
-
-
Hainer, J.S.1
Sherrard, D.J.2
Swan, S.K.3
Barrett, J.S.4
Assaid, C.A.5
Fossler, M.J.6
Cox, D.S.7
Williams, R.M.8
Pittenger, A.L.9
Stephenson, C.A.10
Hua, T.A.11
-
11
-
-
0025923636
-
Delayed elimination of enoxaparin in patients with chronic renal insufficiency
-
Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, Vernier I, Boneu B: Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 63:385-390, 1991
-
(1991)
Thromb Res
, vol.63
, pp. 385-390
-
-
Cadroy, Y.1
Pourrat, J.2
Baladre, M.F.3
Saivin, S.4
Houin, G.5
Montastruc, J.L.6
Vernier, I.7
Boneu, B.8
-
12
-
-
0036272018
-
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes
-
Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Elliott MA: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753-759, 2002
-
(2002)
Am Heart J
, vol.143
, pp. 753-759
-
-
Becker, R.C.1
Spencer, F.A.2
Gibson, M.3
Rush, J.E.4
Sanderink, G.5
Murphy, S.A.6
Ball, S.P.7
Elliott, M.A.8
-
13
-
-
0022878856
-
Low molecular weight heparin half life is prolonged in haemodialysed patients
-
Goudable C, Ton That H, Damani A, Durand D, Caranobe C, Sie P, Boneu B: Low molecular weight heparin half life is prolonged in haemodialysed patients. Thromb Res 43:1-5, 1986
-
(1986)
Thromb Res
, vol.43
, pp. 1-5
-
-
Goudable, C.1
Ton That, H.2
Damani, A.3
Durand, D.4
Caranobe, C.5
Sie, P.6
Boneu, B.7
-
14
-
-
0036049628
-
Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin
-
Bastani B, Gonzalez E: Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin. Am J Nephrol 22:403-404, 2002
-
(2002)
Am J Nephrol
, vol.22
, pp. 403-404
-
-
Bastani, B.1
Gonzalez, E.2
-
15
-
-
0037049342
-
Is impaired renal function a contraindication to the use of low-molecular-weight heparin?
-
Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605-2609, 2002
-
(2002)
Arch Intern Med
, vol.162
, pp. 2605-2609
-
-
Nagge, J.1
Crowther, M.2
Hirsh, J.3
-
16
-
-
0033710044
-
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days
-
Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P: Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84:800-804, 2000
-
(2000)
Thromb Haemost
, vol.84
, pp. 800-804
-
-
Siguret, V.1
Pautas, E.2
Fevrier, M.3
Wipff, C.4
Durand-Gasselin, B.5
Laurent, M.6
Andreux, J.P.7
D'Urso, M.8
Gaussem, P.9
-
17
-
-
0025779064
-
Pharmacokinetics of a very low molecular weight heparin in chronic renal failure
-
Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B: Pharmacokinetics of a very low molecular weight heparin in chronic renal failure. Thromb Res 63:311-317, 1991
-
(1991)
Thromb Res
, vol.63
, pp. 311-317
-
-
Hory, B.1
Claudet, M.H.2
Magnette, J.3
Bechtel, P.4
Bayrou, B.5
-
18
-
-
0025945703
-
Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure
-
Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM: Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 59:543-545, 1991
-
(1991)
Nephron
, vol.59
, pp. 543-545
-
-
Goudable, C.1
Saivin, S.2
Houin, G.3
Sie, P.4
Boneu, B.5
Tonthat, H.6
Suc, J.M.7
-
19
-
-
0033923679
-
Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency
-
Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF: Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775, 2000
-
(2000)
Pharmacotherapy
, vol.20
, pp. 771-775
-
-
Gerlach, A.T.1
Pickworth, K.K.2
Seth, S.K.3
Tanna, S.B.4
Barnes, J.F.5
-
20
-
-
0035210952
-
Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: A report of two cases
-
Dabney A, Bastani B: Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases. Intensive Care Med 27:1954-1957, 2001
-
(2001)
Intensive Care Med
, vol.27
, pp. 1954-1957
-
-
Dabney, A.1
Bastani, B.2
-
21
-
-
0033624537
-
Enoxaparin associated with huge abdominal wall hematomas: A report of two cases
-
Antonelli D, Fares L 2nd, Anene C: Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg 66:797-800, 2000
-
(2000)
Am Surg
, vol.66
, pp. 797-800
-
-
Antonelli, D.1
Fares II, L.2
Anene, C.3
-
22
-
-
0035056845
-
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin
-
Busby LT, Weyman A, Rodgers GM: Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67:54-56, 2001
-
(2001)
Am J Hematol
, vol.67
, pp. 54-56
-
-
Busby, L.T.1
Weyman, A.2
Rodgers, G.M.3
-
23
-
-
10744228663
-
Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease
-
Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, Kalra PA, Waldek S, O'Donoghue DJ, Wood GN: Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 43:531-537, 2004
-
(2004)
Am J Kidney Dis
, vol.43
, pp. 531-537
-
-
Farooq, V.1
Hegarty, J.2
Chandrasekar, T.3
Lamerton, E.H.4
Mitra, S.5
Houghton, J.B.6
Kalra, P.A.7
Waldek, S.8
O'Donoghue, D.J.9
Wood, G.N.10
-
24
-
-
0035522327
-
Choosing a parenteral anticoagulant agent
-
Diuguid DL: Choosing a parenteral anticoagulant agent. N Engl J Med 345:1340-1342, 2001
-
(2001)
N Engl J Med
, vol.345
, pp. 1340-1342
-
-
Diuguid, D.L.1
-
25
-
-
0033034039
-
Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
-
Dunn AS, Coller B: Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 106:660-669, 1999
-
(1999)
Am J Med
, vol.106
, pp. 660-669
-
-
Dunn, A.S.1
Coller, B.2
-
26
-
-
0035142879
-
Dosing and monitoring of low-molecular-weight heparins in special populations
-
Duplaga BA, Rivers CW, Nutescu E: Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21:218-234, 2001
-
(2001)
Pharmacotherapy
, vol.21
, pp. 218-234
-
-
Duplaga, B.A.1
Rivers, C.W.2
Nutescu, E.3
-
27
-
-
0037021568
-
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
-
Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D: A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 40:1943-1950, 2002
-
(2002)
J Am Coll Cardiol
, vol.40
, pp. 1943-1950
-
-
Choussat, R.1
Montalescot, G.2
Collet, J.P.3
Vicaut, E.4
Ankri, A.5
Gallois, V.6
Drobinski, G.7
Sotirov, I.8
Thomas, D.9
-
28
-
-
0037219097
-
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
-
Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, Thomas D: Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 41:8-14, 2003
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 8-14
-
-
Collet, J.P.1
Montalescot, G.2
Fine, E.3
Golmard, J.L.4
Dalby, M.5
Choussat, R.6
Ankri, A.7
Dumaine, R.8
Lesty, C.9
Vignolles, N.10
Thomas, D.11
-
29
-
-
0037485598
-
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies
-
Spinier SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33-41, 2003
-
(2003)
Am Heart J
, vol.146
, pp. 33-41
-
-
Spinier, S.A.1
Inverso, S.M.2
Cohen, M.3
Goodman, S.G.4
Stringer, K.A.5
Antman, E.M.6
-
30
-
-
0041358575
-
Review of antithrombotic agents used for acute coronary syndromes in renal patients
-
Fernandez JS, Sadaniantz BT, Sadaniantz A: Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis 42:446-455, 2003
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 446-455
-
-
Fernandez, J.S.1
Sadaniantz, B.T.2
Sadaniantz, A.3
-
31
-
-
0345173465
-
-
West Point, PA: Merck and Co., Inc.
-
Tirofiban package insert. West Point, PA: Merck and Co., Inc.
-
Tirofiban Package Insert
-
-
-
32
-
-
0034721399
-
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
-
Bhatt DL, Topol EJ: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284:1549-1558, 2000
-
(2000)
JAMA
, vol.284
, pp. 1549-1558
-
-
Bhatt, D.L.1
Topol, E.J.2
-
33
-
-
0031596967
-
Disposition of 14C-eptifibatide after intravenous administration to healthy men
-
Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE: Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 20:307-323, 1998
-
(1998)
Clin Ther
, vol.20
, pp. 307-323
-
-
Alton, K.B.1
Kosoglou, T.2
Baker, S.3
Affrime, M.B.4
Cayen, M.N.5
Patrick, J.E.6
-
34
-
-
0042165874
-
Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: Prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis
-
Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr: Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Cathet Cardiovasc Interv 59:459-462, 2003
-
(2003)
Cathet Cardiovasc Interv
, vol.59
, pp. 459-462
-
-
Sperling, R.T.1
Pinto, D.S.2
Ho, K.K.3
Carrozza Jr., J.P.4
-
35
-
-
18744392239
-
Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: Incidence and multivariate risk factors
-
Rasty S, Borzak S, Tisdale JE: Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol 42:1366-1373, 2002
-
(2002)
J Clin Pharmacol
, vol.42
, pp. 1366-1373
-
-
Rasty, S.1
Borzak, S.2
Tisdale, J.E.3
-
36
-
-
0037420072
-
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
-
Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 718-724
-
-
Freeman, R.V.1
Mehta, R.H.2
Al Badr, W.3
Cooper, J.V.4
Kline-Rogers, E.5
Eagle, K.A.6
-
37
-
-
0037083099
-
Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab
-
Frilling B, Zahn R, Fraiture B, Mark B, Donges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J: Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 89:450-452, 2002
-
(2002)
Am J Cardiol
, vol.89
, pp. 450-452
-
-
Frilling, B.1
Zahn, R.2
Fraiture, B.3
Mark, B.4
Donges, K.5
Becker, T.6
Siegler, K.E.7
Seidl, K.8
Rustige, J.9
Senges, J.10
-
38
-
-
0037094157
-
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
-
Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG: Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 89:1209-1211, 2002
-
(2002)
Am J Cardiol
, vol.89
, pp. 1209-1211
-
-
Jeremias, A.1
Bhatt, D.L.2
Chew, D.P.3
Ziada, K.M.4
Albirini, A.5
Brener, S.J.6
Lincoff, A.M.7
Topol, E.J.8
Ellis, S.G.9
-
39
-
-
0037218936
-
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial)
-
Reddan DN, O'Shea JC, Sarembock IJ, Williams KA, Pieper KS, Santoian E, Owen WF, Kitt MM, Tcheng JE: Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). Am J Cardiol 91:17-21, 2003
-
(2003)
Am J Cardiol
, vol.91
, pp. 17-21
-
-
Reddan, D.N.1
O'Shea, J.C.2
Sarembock, I.J.3
Williams, K.A.4
Pieper, K.S.5
Santoian, E.6
Owen, W.F.7
Kitt, M.M.8
Tcheng, J.E.9
-
40
-
-
0041488808
-
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions
-
Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR Jr, Berger PB: Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 146:345-350, 2003
-
(2003)
Am Heart J
, vol.146
, pp. 345-350
-
-
Best, P.J.1
Lennon, R.2
Gersh, B.J.3
Ting, H.H.4
Rihal, C.S.5
Bell, M.R.6
Herzog, C.A.7
Holmes Jr., D.R.8
Berger, P.B.9
-
41
-
-
0037150156
-
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial
-
Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 105:2361-2366, 2002
-
(2002)
Circulation
, vol.105
, pp. 2361-2366
-
-
Januzzi Jr., J.L.1
Snapinn, S.M.2
DiBattiste, P.M.3
Jang, I.K.4
Theroux, P.5
-
42
-
-
0037118664
-
Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?
-
Quinn MJ, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106:379-385, 2002
-
(2002)
Circulation
, vol.106
, pp. 379-385
-
-
Quinn, M.J.1
Plow, E.F.2
Topol, E.J.3
-
43
-
-
0142074359
-
Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: Appropriate interpretation of the guidelines
-
Antman EM: Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Am Heart J 146(suppl 4):S18-S22, 2003
-
(2003)
Am Heart J
, vol.146
, Issue.4 SUPPL.
-
-
Antman, E.M.1
|